The study focused on a certain type of biomolecule built like a nano-Christmas tree. Called a glycoconjugate, it's many branches are bedecked with sugary ornaments.
According to conventional wisdom, the glycoconjugate's lowly "tree" basically holds the sugars in place as they do the important work of reacting with other molecules.
Now, Tarun Dama, a biochemist at Michigan Technological University has discovered that the tree itself - called the scaffold - is a good deal more than a simple prop.
"People didn't appreciate that the scaffolds were active," said Dam.
The discovery opens up new avenues for research, in particular the development of more and better pharmaceuticals.
Glycoconjugates are found naturally in the body, but they are also an important class of drugs that includes anything from cancer treatments to vaccines.
To determine if the scaffold had a role to play in biological reactions, Dam and his team built and tested two types of glycoconjugate molecules.
The scientists then tested how the different glycoconjugates reacted with biomolecules called lectins.
Lectins play an important role in numerous biological processes and are a target for many glycoconjugate drugs.
If the scaffolds had been inert, the reactions would have been identical. However, the sugars on the protein scaffold reacted with the lectins differently.
"If the scaffolds are different, they can cause my drug to work one way and your drug to work another way, even though they have similar epitopes (sugars)," Dam said.
The research was published in the journal Biochemistry.
You’ve reached your limit of {{free_limit}} free articles this month.
Subscribe now for unlimited access.
Already subscribed? Log in
Subscribe to read the full story →
Smart Quarterly
₹900
3 Months
₹300/Month
Smart Essential
₹2,700
1 Year
₹225/Month
Super Saver
₹3,900
2 Years
₹162/Month
Renews automatically, cancel anytime
Here’s what’s included in our digital subscription plans
Exclusive premium stories online
Over 30 premium stories daily, handpicked by our editors


Complimentary Access to The New York Times
News, Games, Cooking, Audio, Wirecutter & The Athletic
Business Standard Epaper
Digital replica of our daily newspaper — with options to read, save, and share


Curated Newsletters
Insights on markets, finance, politics, tech, and more delivered to your inbox
Market Analysis & Investment Insights
In-depth market analysis & insights with access to The Smart Investor


Archives
Repository of articles and publications dating back to 1997
Ad-free Reading
Uninterrupted reading experience with no advertisements


Seamless Access Across All Devices
Access Business Standard across devices — mobile, tablet, or PC, via web or app
